Chugai Pharmaceutical Co., Ltd. CHGCF
OTC PK
| 06/30/2026 | 12/31/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Revenue | 1.73B | 1.84B | 1.74B | 1.70B | |
| Total Other Revenue | 418.49M | 409.33M | 265.09M | 188.57M | |
| Total Revenue | 2.14B | 2.25B | 2.01B | 1.89B | |
| Cost of Revenue | 654.14M | 568.15M | 609.76M | 576.28M | |
| Gross Profit | 1.49B | 1.68B | 1.40B | 1.32B | |
| SG&A Expenses | 182.30M | 239.60M | 196.71M | 152.48M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -1.83M | 2.63M | -61.14M | -1.17M | |
| Total Operating Expenses | 1.13B | 1.15B | 1.06B | 996.14M | |
| Operating Income | 1.01B | 1.10B | 946.41M | 896.67M | |
| Income Before Tax | 1.06B | 1.10B | 941.63M | 891.28M | |
| Income Tax Expenses | 330.74M | 269.25M | 268.96M | 253.25M | |
| Earnings from Continuing Operations | 730.17M | 833.22M | 672.67M | 638.03M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | 730.17M | 833.22M | 672.67M | 638.03M | |
| EBIT | 1.01B | 1.10B | 946.41M | 896.67M | |
| EBITDA | 1.01B | 1.30B | 949.18M | 899.30M | |
| EPS Basic | 0.44 | 0.51 | 0.41 | 0.39 | |
| Normalized Basic EPS | 0.40 | 0.42 | 0.36 | -- | |
| EPS Diluted | 0.44 | 0.51 | 0.41 | 0.39 | |
| Normalized Diluted EPS | 0.40 | 0.42 | 0.36 | -- | |
| Average Basic Shares Outstanding | 1.65B | 1.65B | 1.65B | 1.65B | |
| Average Diluted Shares Outstanding | 1.65B | 1.65B | 1.65B | 1.65B | |
| Dividend Per Share | 0.41 | 0.47 | 0.35 | -- | |
| Payout Ratio | -- | -- | 0.45% | -- | |